Literature DB >> 20504235

Successful treatment of disseminated human papillomavirus infection with pegylated interferon and ribavirin.

Nabin K Shrestha1, David J Hamrock.   

Abstract

We report a case of disseminated human papillomavirus infection that developed in a patient while receiving efalizumab for the treatment of psoriasis. This infection progressed for several months after efalizumab treatment had been stopped. All human papillomavirus lesions completely resolved after 10 weeks of therapy with a combination of pegylated interferon and ribavirin.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20504235     DOI： 10.1086/653428

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  5 in total

1.  Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin.

Authors:  Theodore R Miller; Jeffrey J Weiss; Norbert Bräu; Douglas T Dieterich; Alicia Stivala; Monica Rivera-Mindt
Journal:  J Neurovirol       Date:  2016-11-28       Impact factor: 2.643

2.  Multimethod assessment of baseline depression and relationship to hepatitis C treatment discontinuation.

Authors:  Jeffrey J Weiss; Sarah Prieto; Norbert Bräu; Douglas T Dieterich; Sue M Marcus; Alicia Stivala; Jack M Gorman
Journal:  Int J Psychiatry Med       Date:  2018-01-03       Impact factor: 1.210

Review 3.  Interferons as therapeutic agents for infectious diseases.

Authors:  Scott J Bergman; McKenzie C Ferguson; Cathy Santanello
Journal:  Infect Dis Clin North Am       Date:  2011-12       Impact factor: 5.982

Review 4.  Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance.

Authors:  Stéphanie Beaucourt; Marco Vignuzzi
Journal:  Curr Opin Virol       Date:  2014-05-19       Impact factor: 7.090

Review 5.  Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.

Authors:  Maryam Dadar; Sandip Chakraborty; Kuldeep Dhama; Minakshi Prasad; Rekha Khandia; Sameer Hassan; Ashok Munjal; Ruchi Tiwari; Kumaragurubaran Karthik; Deepak Kumar; Hafiz M N Iqbal; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2018-11-12       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.